Yi-Long Wu mostly deals with Lung cancer, Internal medicine, Oncology, Surgery and Chemotherapy. His Lung cancer research focuses on Gefitinib in particular. Internal medicine is a component of his Carboplatin, Hazard ratio, Pemetrexed, Carcinoma and Erlotinib studies.
His biological study spans a wide range of topics, including Phases of clinical research and Adenocarcinoma. The concepts of his Surgery study are interwoven with issues in Gastroenterology, Placebo, Clinical trial and Icotinib. Yi-Long Wu has researched Epidermal growth factor receptor in several fields, including Tyrosine kinase and Cancer research.
Internal medicine, Lung cancer, Oncology, Cancer research and Chemotherapy are his primary areas of study. Internal medicine is often connected to Surgery in his work. His Lung cancer study integrates concerns from other disciplines, such as Cancer, Epidermal growth factor receptor and Adenocarcinoma.
His research in Epidermal growth factor receptor intersects with topics in Tyrosine kinase and Tyrosine-kinase inhibitor. His Oncology research incorporates elements of Carboplatin, Clinical endpoint, Clinical trial and Carcinoma. Yi-Long Wu combines subjects such as Mutation, KRAS, Anaplastic lymphoma kinase, Crizotinib and Immunotherapy with his study of Cancer research.
His primary areas of study are Internal medicine, Oncology, Lung cancer, Cancer research and Chemotherapy. His study in Gefitinib, Hazard ratio, Clinical endpoint, Lung and Tolerability falls within the category of Internal medicine. His Oncology study combines topics in areas such as Adjuvant therapy and Clinical trial, Phases of clinical research.
His Lung cancer research is multidisciplinary, incorporating elements of Cancer, Epidermal growth factor receptor, Adverse effect and Exon. Yi-Long Wu interconnects Tyrosine kinase, T cell, Anaplastic lymphoma kinase, Carcinoma and Crizotinib in the investigation of issues within Cancer research. His studies in Chemotherapy integrate themes in fields like Retrospective cohort study and Overall survival.
His scientific interests lie mostly in Internal medicine, Oncology, Lung cancer, Cancer research and Chemotherapy. His studies deal with areas such as Lung, Cohort and Immunotherapy as well as Oncology. His study in Lung cancer focuses on Non small cell in particular.
His research on Cancer research also deals with topics like
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony S. Mok;Yi Long Wu;Sumitra Thongprasert;Chih Hsin Yang.
The New England Journal of Medicine (2009)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw;Dong Wan Kim;Kazuhiko Nakagawa;Takashi Seto.
The New England Journal of Medicine (2013)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou;Yi Long Wu;Gongyan Chen;Jifeng Feng.
Lancet Oncology (2011)
First-line crizotinib versus chemotherapy in ALK-positive lung cancer
Benjamin J. Solomon;Tony Shu-kam Mok;Dong Wan Kim;Yi Long Wu.
The New England Journal of Medicine (2014)
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Tony S. Mok;Yi Long Wu;Myung Ju Ahn;Marina C. Garassino.
The New England Journal of Medicine (2017)
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.
Peter Goldstraw;Kari Chansky;John Crowley;Ramon Rami-Porta.
Journal of Thoracic Oncology (2016)
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Edward S. Kim;Vera Hirsh;Tony Mok;Mark A. Socinski.
The Lancet (2008)
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Tudor Ciuleanu;Thomas Brodowicz;Christoph Zielinski;Joo Hang Kim.
The Lancet (2009)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S.K. Mok;Yi Long Wu;Iveta Kudaba;Dariusz M. Kowalski.
The Lancet (2019)
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Wu;Caicun Zhou;Cheng-Ping Hu;Jifeng Feng.
Lancet Oncology (2014)
Annals of Oncology
(Impact Factor: 51.769)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: